Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 19, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for obesity and...
November 18, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in Upcoming December Healthcare Investment Conferences

SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
November 14, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

SAN DIEGO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
November 07, 2024 16:01 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (NASDAQ: SKYE) (“Skye” or the “Company”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways...
November 04, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Demonstrates Prominent Role of Peripheral CB1 Inhibition and Achieves Significant Weight Loss with Novel CB1-inhibiting Antibody, Nimacimab, in Preclinical Model

Peripherally-restricted nimacimab achieves significant dose-dependent weight loss, fat mass reduction, lean mass preservation, and glycemic control in diet-induced obesity model Preliminary data...
November 01, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Announce Third Quarter 2024 Results

SAN DIEGO, Nov. 01, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
October 29, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board

SAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
October 21, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience to Participate in Upcoming November Healthcare Investment Conferences

SAN DIEGO, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...
September 23, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Comments on Monlunabant Phase 2 Top-line Data and Reiterates Confidence in Nimacimab Clinical Development Plan

16-week top-line weight loss data validates mechanism of action targeting peripheral CB1 receptors Skye highlights safety advantages of large-molecule CB1 inhibition compared to small-molecule...
September 03, 2024 07:00 ET | Source: Skye Bioscience, Inc.

Skye Bioscience Appoints Puneet S. Arora, MD, as Chief Medical Officer

SAN DIEGO, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye”), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic...